Lim Yoojoo, Lee Jeong Ok, Bang Soo Mee
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
J Korean Med Sci. 2016 Oct;31(10):1579-85. doi: 10.3346/jkms.2016.31.10.1579.
The nationwide statistical analysis of each disease of classical myeloproliferative neoplasm (MPN) in Korea has not been reported yet. To this end, we have analyzed incidence rates, survival rates and treatment pattern of polycythemia vera (PV), primary myelofibrosis (MF) and essential thrombocythemia (ET) using Korea National Cancer Incidence Database (KNCIDB) and Health Insurance Review and Assessment Service (HIRA) database. Between 2003 and 2011, a total of 4,342 new cases of MPN were reported to the KNCIDB. ET was the most common, followed by MF and PV. The crude incidence rates for PV, MF, and ET have increased during the period, reaching 0.40, 0.15, and 0.84 per 100,000, respectively. Five-year relative survival rate of all MPN patients was 89.3%, with lowest relative survival rate with MF (53.1%). The prevalence of each disease estimated from HIRA data also increased during the study period. Notably, ET was found to be most prevalent. The prescription rate of hydroxyurea and phlebotomy to PV, MF and ET patients remained constant over the period, and the prescription rate of hydroxyurea was higher in patients with age over 60 years. This is the first Korean nationwide statistics of MPN, using central registry data. This set of data can be utilized to compare the Korean MPN status to international data and guidelines.
韩国尚未有关于经典型骨髓增殖性肿瘤（MPN）各疾病的全国性统计分析报告。为此，我们利用韩国国家癌症发病率数据库（KNCIDB）和健康保险审查与评估服务（HIRA）数据库，分析了真性红细胞增多症（PV）、原发性骨髓纤维化（MF）和原发性血小板增多症（ET）的发病率、生存率及治疗模式。2003年至2011年期间，KNCIDB共报告了4342例新的MPN病例。ET最为常见，其次是MF和PV。在此期间，PV、MF和ET的粗发病率均有所上升，分别达到每10万人0.40、0.15和0.84。所有MPN患者的五年相对生存率为89.3%，其中MF的相对生存率最低（53.1%）。根据HIRA数据估算的各疾病患病率在研究期间也有所上升。值得注意的是，ET最为普遍。在此期间，PV、MF和ET患者使用羟基脲和放血疗法的处方率保持不变，60岁以上患者使用羟基脲的处方率更高。这是韩国首次利用中央登记数据对MPN进行全国性统计。这组数据可用于将韩国MPN的状况与国际数据和指南进行比较。
